Shell Asset Management Co
- SEC CIK
- 0001211028
- Latest filing
- Nov 7, 2025
CHRS holding history
Coherus Oncology, Inc. in every 13F filed by Shell Asset Management Co, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
CHRS overviewAll 13F holders of CHRSFull Q3 2025 holdings
- Shares (Q3 2025)
- 0
- Sold out in Q3 2025
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 17
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q3 2025 | 0 | $0 | 0.0% | −9,137−100.0% | Sold out | Holders |
| Q2 2025 | 9,137 | $7.00K | <0.1% | −7,847−46.2% | Reduced | Holders |
| Q1 2025 | 16,984 | $14.0K | <0.1% | −570−3.2% | Reduced | Holders |
| Q4 2024 | 17,554 | $24.0K | <0.1% | 00.0% | Unchanged | Holders |
| Q3 2024 | 17,554 | $18.0K | <0.1% | – | No prior filing | Holders |
| Q2 2024 | – | – | – | – | Not filed | Holders |
| Q1 2024 | 15,069 | $26.0K | <0.1% | −1,015−6.3% | Reduced | Holders |
| Q4 2023 | 16,084 | $54.0K | <0.1% | −4,830−23.1% | Reduced | Holders |
| Q3 2023 | 20,914 | $78.0K | <0.1% | −329−1.5% | Reduced | Holders |
| Q2 2023 | 21,243 | $91.0K | <0.1% | −122−0.6% | Reduced | Holders |
| Q1 2023 | 21,365 | $146.0K | <0.1% | −75−0.3% | Reduced | Holders |
| Q4 2022 | 21,440 | $170.0K | <0.1% | −4,353−16.9% | Reduced | Holders |
| Q3 2022 | 25,793 | $248.0K | <0.1% | −6,760−20.8% | Reduced | Holders |
| Q2 2022 | 32,553 | $236.0K | <0.1% | +55+0.2% | Added | Holders |
| Q1 2022 | 32,498 | $420.0K | <0.1% | −4,809−12.9% | Reduced | Holders |
| Q4 2021 | 37,307 | $595.0K | <0.1% | +179+0.5% | Added | Holders |
| Q3 2021 | 37,128 | $597.0K | <0.1% | −1,600−4.1% | Reduced | Holders |
| Q2 2021 | 38,728 | $536.0K | <0.1% | +2,100+5.7% | Added | Holders |
| Q1 2021 | 36,628 | $535.0K | <0.1% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.